(Q53921466)

22 May 2018

title

Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. (English)

1 reference

22 May 2018

borderline personality disorder

main subject

patient

0 references

0 references

author name string

S C Schulz

1

1 reference

22 May 2018

K L Camlin

2

1 reference

22 May 2018

S A Berry

3

1 reference

22 May 2018

J A Jesberger

4

1 reference

22 May 2018

language of work or name

English

0 references

publication date

1 November 1999

1 reference

22 May 2018

published in

Biological Psychiatry

1 reference

22 May 2018

volume

46

1 reference

22 May 2018

issue

10

1 reference

22 May 2018

page(s)

1429-1435

1 reference

22 May 2018

The schedule for Schizotypal Personalities (SSP): a diagnostic interview for schizotypal features

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

FACTOR ANALYSIS OF SOME PSYCHOMETRIC MEASURES OF IMPULSIVENESS AND ANXIETY.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Low-Dose Neuroleptic Regimens in the Treatment of Borderline Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Fluoxetine and impulsive aggressive behavior in personality-disordered subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Continuation pharmacotherapy of borderline personality disorder with haloperidol and phenelzine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Pharmacotherapy of borderline personality disorder. Alprazolam, carbamazepine, trifluoperazine, and tranylcypromine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Clozapine treatment of borderline patients: a preliminary study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Borderline and schizotypal personality disorders treated with low-dose thiothixene vs placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Defining borderline patients: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

The diagnostic interview for borderline patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Pseudoneurotic forms of schizophrenia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Neuroleptic treatment of schizotypal personality disorders.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Borderline personality organization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Psychiatric diagnosis and a typology of clinical drug effects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Cognitive-Behavioral Treatment of Chronically Parasuicidal Borderline Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Fluoxetine in the treatment of borderline and schizotypal personality disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Fluoxetine in borderline personality disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Lithium Carbonate in Emotionally Unstable Character Disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Response of borderline and schizotypal patients to small doses of thiothixene and haloperidol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Efficacy of phenelzine and haloperidol in borderline personality disorder

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Progress in pharmacotherapy of borderline disorders. A double-blind study of amitriptyline, haloperidol, and placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Paradoxical effects of amitriptyline on borderline patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

Is there any drug treatment of choice for the borderline patient?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2899%2900128-6

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/S0006-3223(99)00128-6

1 reference

22 May 2018

PubMed ID

10578457

1 reference

22 May 2018